Civil Liability for the Trade of Unlicensed Medicines: A Comparative Study
DOI:
https://doi.org/10.25130/b4wam586Keywords:
-- Civil Liability - Drug Circulation - Unofficial Medicines - Safety Obligation - Safety Obligation.Abstract
: This research examines the civil liability arising from the circulation of unofficial medicines in the Iraqi private sector—medicines traded outside approved regulatory frameworks, posing a direct threat to public health. The problem lies in the inadequacy of traditional rules to address risks resulting from complex supply chains, personal importation, and electronic platforms, raising questions about identifying the parties legally responsible for compensating the patient. The study adopted a comparative analytical approach between Iraqi, French, and American laws, applying these texts to the reality of pharmaceutical regulation and the guidelines issued by the Iraqi Ministry of Health. The research concluded that the unique nature of medicine necessitates stricter liability standards for suppliers and pharmacists when violating mandatory registration and importation pathways, while granting the judge broad discretionary power to ensure full compensation for the victim. The study recommended updating legislative frameworks to include product liability and activating proactive regulatory mechanisms to protect consumers from the risks of medicines of unknown origin.
© 2023 TUJR, College of Law, Tikrit University
References
Books:
1- Han W. Choi and Jae Hong Lee, Pharmaceutical Product Liability, Greenwich, CT: Oracle Investment Management; San Diego, CA: Morrison & Foerster, L.L.P., 2011.
2- Philippe le Tourneau, Droit de la responsabilité et des contrats: Régimes d’indemnisation, 12e éd., Paris: Dalloz, 2020.
3- Lionel D. Edwards et al., Principles and Practice of Pharmaceutical Medicine, 3rd ed., Blackwell Publishing Ltd, 2011.
Statutes and Codes:
1- World Health Organization, Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions, WHO Press, Geneva, 2010.
2- World Health Organization, Substandard and Falsified Medical Products: Strengthening Oversight and Supply Chains, WHO Press, Geneva, 2023.
3-Chatham House, Combatting Counterfeit and Substandard Medicines: Global Supply Chain Challenges, Royal Institute of International Affairs, London, 2022.
4-Financial Action Task Force FATF, Money Laundering and Terrorist Financing Risks Arising from Illicit Financial Flows, FATF Publishing, Paris, 2024.
5-France, Code de la Santé Publique, Dalloz, 2025.
6-France, Code de la Santé Publique, art. L.5111-1, Dalloz, 2025.
7-France, Code civil français, art. 1245-17 (modifié par Ordonnance n°2016-131 du 10 février 2016.
8-United States, Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 301 et seq.
Research Papers and Articles:
1- Al-Jumaili, Ali, et al, Challenges to the Pharmaceutical Supply Chain in Iraq: A Qualitative Study, Journal of Pharmaceutical Policy and Practice, 2021.
2- Mello, Michelle M, et al, The Role of Law in Population Health: There is No I in Health, The Lancet Public Health, 2017.
3- Mello, Michelle M, et al, Drug Pricing and Value, Strategies for Lowering Cost and Maintaining Innovation, New England Journal of Medicine, 2017.
4- Ausness, Richard C, The Right of Publicity: A Case Study in Legal Change, South Carolina Law Review, 2022.
5- Choi, Han W, and Lee, Jae Hong, Drug importation: limitations of current proposals and opportunities for improvement, Blood Cancer Journal, 2021.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
تنشر مجلة جامعة تكريت للحقوق جميع المقالات بنظام الوصول المفتوح الفوري وفق رخصة المشاع الإبداعي نَسب المُصنَّف 4.0 الدولية (CC BY 4.0). يحتفظ المؤلفون بحقوق النشر، ويجوز للآخرين مشاركة العمل وتكييفه بشرط الإسناد الصحيح للمؤلف والمجلة وبيان أي تغييرات.